MedTrace Logo

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

NCT05037149 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-03-18

No results posted yet for this study

Summary

An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.

Conditions

Interventions

DRUG

STP707

STP707 Powder for Injection

Sponsors & Collaborators

  • Sirnaomics

    lead INDUSTRY

Principal Investigators

  • Andrae Vandross, MD · NEXT Oncology

  • Jason Henry, MD · Sarah Cannon Research Institute at HealthONE

  • Anthony El-Khoueiry, MD · University of Southern California

  • Angela Alistar, MD · Atlantic Health System

  • Hani Babiker, MD · Mayo Clinic

  • Michael Cecchini, MD · Yale University

  • Conor Steuer, MD · Emory University

  • Christina Wu, MD · Mayo Clinic

  • Zhaohui Jin, MD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2024-03-30
Completion
2024-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05037149 on ClinicalTrials.gov